

in 2019. RNA interference studies using small molecules have also been completed in sheep and non-human primate models of Huntington's disease. Experimental therapeutics in Huntington's disease are approaching a historical peak and outcomes over the next few years will define the therapeutic options available for affected families. Partnership among Huntington's disease volunteers and investigators is crucial to meet the enrolment demands of clinical trials.

*Jane S Paulsen, Christopher S Coffey

Department of Neurology, Psychiatry, Psychological and Brain Sciences (JSP) and Department of Biostatistics (CSC), University of Iowa, Iowa City, IA 52242, USA (JSP)
jane-paulsen@uiowa.edu

We declare no competing interests.

- 1 Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. *Neurology* 2006; **66**: 366–72.
- 2 Huntington Study Group, Frank S, Testa CM, et al. Effect of deutetabenazine on chorea among patients with Huntington disease: a randomized clinical trial. *JAMA* 2016; **316**: 40–50.
- 3 Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting huntingtin expression in patients with Huntington's disease. *N Engl J Med* 2019; **380**: 2307–16.
- 4 Penney JB Jr, Vonsattel JP, MacDonald ME, et al. CAG repeat number governs the development rate of pathology in Huntington's disease. *Ann Neurol* 1997; **41**: 689–92.
- 5 Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive clinical trials: the Predict-HD study. *Arch Neurol* 2006; **63**: 883–90.



Thank you to our peer reviewers in 2018

The Lancet Neurology is proud to be the leading clinical neurology journal, according to the 2018 Journal Citation Report, for another successive year. This achievement is, in great part, due to the clinical and statistical reviewers from around the world who have provided the expert advice to ensure publication of the highest quality articles for our readers. The names of everyone who reviewed papers for the journal throughout 2018 are listed in the appendix; those who reviewed five papers, or more, are marked with an asterisk. We extend our warmest gratitude to all these reviewers.

We also recognise that we have a responsibility to our community for equal opportunities. *The Lancet* Group has drawn attention to the evidence that shows women to be vastly under-represented as authors, reviewers, or editorial board members across scientific and medical journals, noting that these inequities are at odds with our values and track record of advocacy.¹ In 2018, around 22% of our reviewers were women. This number falls short in relation to the estimated proportion of around 30% of female neurologists in the USA in 2017, reported by the Association of American Medical Colleges.² We aim to facilitate women's participation in peer review and any other of our editorial initiatives.

In this vein, *The Lancet* Group has made a commitment to increase gender equity, diversity, and inclusion in research and publishing, announcing a new Diversity Pledge and a No All-Male Panel Policy.³ The Diversity Pledge expresses our commitment to increasing the representation of women and colleagues from low-income and middle-income countries among our editors, advisors, peer reviewers, and authors. The No All-Male Panel Policy states that *Lancet* Group editors will not serve as panellists at a public conference or event when there are no women on the panel, and commits us to gender balance on events we organise. *The Lancet Neurology* is committed to these pledges and we hope other journals in our field will follow suit.

Laura Hart

Acting Deputy Editor, *The Lancet Neurology*, London, EC2Y 5AS, UK
laura.hart@lancet.com

- 1 Clark J, Horton R. What is *The Lancet* doing on gender and diversity? *Lancet* 2019; **393**: 508–10.
- 2 Association of American Medical Colleges. 2018 AAMC Physician Specialty Data Report. Available at <https://www.aamc.org/data/workforce/reports/492536/2018-physician-specialty-data-report.html> (accessed July 30, 2019).
- 3 The Lancet. The *Lancet* Group's commitments to gender equity and diversity. *Lancet* 2019; **394**: 452–53.

See Online for appendix